Recombinant Human Cyclin-Dependent Kinase Inhibitor 2A, Isoform 1-TAT
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
细胞周期蛋白依赖性激酶抑制因子(CDKI)是与CDKs结合并抑制CDKs活性的蛋白质。已经确定了两类主要的CDK抑制剂。P16家族(p15、p16、p18和p19)结合并抑制CDK4和CDK6的活性。P21家族(p21、p27、p28和p57)可以与广泛的CDK-Cyclin复合体结合并抑制其活性。CDKI能够抑制生长，几条证据有力地表明，至少一些CDKI可能是肿瘤抑制蛋白。P16-Ink4a是人类p16家族的成员，由CDKN2A基因编码。它有三种亚型，它们在大脑或骨骼肌中广泛表达，但没有检测到，除了亚型3是胰腺特异的。P16INK4A基因缺陷是导致Li-Fraumeni综合征(LFS)和黑色素瘤-星形细胞瘤综合征(MASS)的原因之一。TAT转导肽可以帮助rHuP16-INK4a在体内跨越各种生物膜，对蛋白质的超结构没有影响。
Reference
1. Buda G, Maggini V, Galimberti S, et al. 2007. Leuk Res, 31: 569-70
2. Komiya A, Suzuki H, Aida S, et al. 1995. Jpn J Cancer Res, 86: 622-5
3. Jares P, Fernandez PL, Nadal A, et al. 1997. Oncogene, 15: 1445-53
4. Mori T, Miura K, Aoki T, et al. 1994. Cancer Res, 54: 3396-7.
| Alternate Names | CDK4I, MTS-1, p16INK4A |
| Source | Escherichia coli. |
| M.Wt | Approximately18.0 kDa, a single non-glycosylated polypeptide chain containing 167 amino acids. |
| AA Sequence | EPAAGSSMEP SADWLATAAA RGRVEEVRAL LEAGALPNAP NSYGRRPIQV MMMGSARVAE LLLLHGAEPN CADPATLTRP VHDAAREGFL DTLVVLHRAG ARLDVRDAWG RLPVDLAEEL GHRDVARYLR AAAGGTRGSN HARIDAAEGP SDIPDGYGRK KRRQRRR |
| Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in 2 × PBS, pH 7.0. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Biological Activity | Data is not available. |
| Shipping Condition | Gel pack. |
| Handling | Centrifuge the vial prior to opening. |
| Usage | For Research Use Only! Not to be used in humans. |
质量控制和DataSheet
- 批次:
-
纯度 > 95 % by SDS-PAGE and HPLC analyses.
- Datasheet
Endotoxin: Less than 1 EU/μg of rHuP16-INK4a-TAT as determined by LAL method.